Notice to Readers: Updated Guidelines for the Use of Rifamycins for the Treatment of Tuberculosis Among HIV-Infected Patients Taking Protease Inhibitors or Nonnucleoside Reverse Transcriptase Inhibitors
Guidelines for managing the pharmacologic interactions that can result when patients receive protease inhibitors (PIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) for treatment of human immunodeficiency virus (HIV) infection together with rifamycins for the treatment of tuberculosis have been published previously (1,2). New guidelines regarding interactions among these agents, with recommendations for their use from CDC and partners, are available at http://www.cdc.gov/nchstp/tb/tb_hiv_drugs/toc.htm. Information includes initial recommendations for the new PIs lopinavir/ritonavir, atazanavir, and fosamprenavir, and updated recommendations for other dual PI regimens and NNRTIs. The new recommendations expand the use of rifampin with these antiretroviral drugs, which is critical in regions where rifabutin is unavailable. Periodic updates will be posted to the website to provide clinicians with the latest information.
- CDC. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR 1998;47(No. RR-20).
- CDC. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR 2000;49:185--9.
All MMWR HTML versions of articles are electronic conversions from typeset documents.
This conversion might result in character translation or format errors in the HTML version.
Users are referred to the electronic PDF version (http://www.cdc.gov/mmwr)
and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S.
Government Printing Office (GPO), Washington, DC 20402-9371;
telephone: (202) 512-1800. Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to firstname.lastname@example.org.